[Form 3] GlycoMimetics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Effective June 30, 2025, the Statement of Additional Information (SAI) for John Hancock Financial Opportunities Fund (ticker BTO), John Hancock Investors Trust and John Hancock Premium Dividend Fund is updated to reflect two governance changes:

• Paul Lorentz has resigned as a non-independent Trustee of each fund.
• Kristie M. Feinberg, already serving as each fund’s President and CEO of John Hancock Investment Management, has been appointed as a non-independent Trustee effective the same date and will stand for shareholder election in 2026.

The SAI now lists Ms. Feinberg’s extensive leadership background, including her roles at Manulife Investment Management, Invesco and Oppenheimer Funds, underscoring her experience in finance, strategy and product distribution. The board-class assignment for the Financial Opportunities Fund and Premium Dividend Fund places her term expiring in 2026. The John Hancock Fund Complex comprises 186 funds as of April 30, 2025.

No portfolio, financial or strategic policy changes are disclosed; the supplement is solely a board-composition update, to be read in conjunction with the current SAI.

Insights

Corporate Governance Expert

TL;DR: Routine trustee rotation; governance impact minimal, investment thesis unchanged.

The filing records a normal board transition: Paul Lorentz exits, Kristie Feinberg joins as non-independent Trustee while retaining her President role. Her deep asset-management résumé adds relevant expertise, but because she is already the funds’ CEO, her new board seat merely formalizes influence she effectively possessed. No disclosure suggests strategic, fee, or policy adjustments. Closed-end fund investors should view the change as administrative; it neither alters distribution policy nor portfolio management. Oversight independence remains intact, as the majority of Trustees are still independent, so regulatory risk is low.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bispham Barbara Harlin

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/13/2025

3. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)(2)(3)	01/13/2035	Ordinary Shares	106,235	$6.16	D

Explanation of Responses:

1. Effective as of June 13, 2025 (the "Effective Time"), (i) a wholly-owned subsidiary of GlycoMimetics, Inc. ("GlycoMimetics") merged with and into Crescent Biopharma, Inc. ("Pre-Merger Crescent") with Pre-Merger Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the "First Merger"), (ii) immediately thereafter, Pre-Merger Crescent merged with and into a second wholly-owned subsidiary of GlycoMimetics ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Crescent Biopharma Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, GlycoMimetics changed its name to "Crescent Biopharma, Inc." (hereinafter, the "Issuer").

2. This Form gives effect to the Issuer's completion of a conversion from a corporation organized under the laws of the State of Delaware (the "Delaware Corporation") to an exempted company incorporated under the laws of the Cayman Islands (the "Cayman Company"), effective as of June 16, 2025. In connection therewith, each outstanding option or right to acquire shares of common stock of the Delaware Corporation continued in existence in the form of and automatically became an option or right to acquire an equal number of ordinary shares of the Cayman Company under the same terms and conditions.

3. Represents options to purchase the Issuer's ordinary shares received by the Reporting Person in the Merger in exchange for options of Pre-Merger Crescent held by the Reporting Person prior to the Merger. This option will vest as to 25% on January 13, 2026 and in equal monthly installments thereafter through January 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

General Counsel and Corporate Secretary. Exhibit 24 - Power of Attorney

	/s/ Barbara Bispham	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did John Hancock file this 424B3 supplement for BTO?

To disclose the resignation of Trustee Paul Lorentz and the appointment of Kristie M. Feinberg as a non-independent Trustee effective June 30, 2025.

Who is the new Trustee for John Hancock Financial Opportunities Fund (BTO)?

Kristie M. Feinberg, the funds’ current President and CEO of John Hancock Investment Management, became a non-independent Trustee on June 30, 2025.

When will Kristie Feinberg stand for election by shareholders?

Ms. Feinberg is slated for shareholder election in 2026; her board class term expires the same year.

Does the supplement indicate any changes to fund strategy or distributions?

No. The document only updates board composition; it does not announce changes to investment strategy, fees, or distribution policies.

How many funds are in the John Hancock Fund Complex as of April 30, 2025?

The complex consists of 186 funds, including separate series of series mutual funds.